Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Those in this range may, or may not, have symptoms
PROs were measured at baseline and 52 weeks using the SF-36v2 acute form (secondary outcome), EQ-5D-5L, APPADL questionnaire and IW-SP questionnaire (tertiary/exploratory outcomes) and were compared for the tirzepatide-pooled dose group and for each dose of tirzepatide versus insulin lispro at 52 weeks
Sayeed I, Turan N, Stein DG, Wali B
Achbani A, Sine H, Naciri A, Baba MA, Kharbach A, Bouchriti Y, et al
US$ 21.92
US$ 29.96
US$ 29.73
US$ 23.96
US$ 28.08
US$ 23.80
US$ 29.95
US$ 28.81
